A type 2 immune response may help in the treatment of cancer, according to two groundbreaking new studies.
The type 2 response is triggered by parasitic infections, such as worms and, according to the European researchers, has not previously been...
11 months ago
Quizartinib is to be funded by the NHS in England for the treatment of some patients with acute myeloid leukaemia (AML), it has been announced.
The tyrosine-kinase blocker gained regulatory approval in March, and will now be available through the...
11 months ago
